Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTRA1 | Q92743 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 1/20 | 0.43 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.43 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31679039 | 1.00 | KLK7 (0.49) | KLK7KLK5PSMB8PSMB9PSMB5 | |
| SCHEMBL31679025 | 0.97 | KLK7 (0.50) | KLK7KLK5PSMB8PSMB9PSMB5 | |
| SCHEMBL22117454 | 0.93 | PSMB8 (0.46) | PSMB8PSMB9PSMB5CCKBRNPY4R | |
| SCHEMBL22117451 | 0.93 | PSMB8 (0.46) | PSMB8PSMB9PSMB5CCKBRNPY4R | |
| SCHEMBL30341836 | 0.93 | PSMB8 (0.47) | KLK7KLK5PSMB8PSMB9PSMB5 | |
| SCHEMBL30341837 | 0.92 | KLK7 (0.54) | KLK7KLK5PSMB8PSMB9PSMB5 | |
| SCHEMBL31679030 | 0.92 | KLK7 (0.49) | KLK7KLK5PSMB8PSMB9PSMB5 | |
| SCHEMBL22133064 | 0.92 | NPFFR1 (0.45) | PSMB8PSMB9PSMB5CTSLCCKBR | |
| SCHEMBL22133070 | 0.92 | NPFFR1 (0.45) | PSMB8PSMB9PSMB5CTSLCCKBR | |
| SCHEMBL22117376 | 0.92 | CTSL (0.49) | CTSLNPY4RNPFFR1NPFFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404300-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4168423-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | ARG2, NLN, OAT | KLK7 4302/4885KLK5 4778/4885PSMB8 2533/4885 |
| US-12404300-B2 | Mitochondria-targeting peptides | SSBP1, HSPE1, IMMT | KLK7 4426/4885KLK5 4428/4885PSMB8 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.